APA (7th ed.) Citation

Fizazi, K., Shore, N., Smith, M., Tammela, T., Le Berre, M., Petrenciuc, O., . . . Kuss, I. (2020). 633P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial. Annals of Oncology, 31, S522. https://doi.org/10.1016/j.annonc.2020.08.892

Chicago Style (17th ed.) Citation

Fizazi, K., N. Shore, M.R Smith, T.L Tammela, M-A Le Berre, O. Petrenciuc, C. Zurth, and I. Kuss. "633P Tolerability and Treatment Response to Darolutamide (DARO) in Patients with Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in the Phase III ARAMIS Trial." Annals of Oncology 31 (2020): S522. https://doi.org/10.1016/j.annonc.2020.08.892.

MLA (9th ed.) Citation

Fizazi, K., et al. "633P Tolerability and Treatment Response to Darolutamide (DARO) in Patients with Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in the Phase III ARAMIS Trial." Annals of Oncology, vol. 31, 2020, p. S522, https://doi.org/10.1016/j.annonc.2020.08.892.